Decoy Therapeutics Inc.
DCOY
$2.99
$0.010.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 227.60K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 227.60K | -- | -- | -- | -- |
| Cost of Revenue | 1.30M | 116.40K | 116.40K | 116.40K | 116.40K |
| Gross Profit | -1.08M | -116.40K | -116.40K | -116.40K | -116.40K |
| SG&A Expenses | 4.10M | 3.62M | 3.73M | 5.14M | 5.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.33M | 4.66M | 4.10M | 5.57M | 5.68M |
| Operating Income | -6.10M | -4.66M | -4.10M | -5.57M | -5.68M |
| Income Before Tax | -14.45M | -13.03M | -12.52M | -5.00M | -5.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.45 | -13.03 | -12.52 | -5.00 | -5.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.45M | -13.03M | -12.52M | -5.00M | -5.10M |
| EBIT | -6.10M | -4.66M | -4.10M | -5.57M | -5.68M |
| EBITDA | -6.07M | -4.65M | -4.09M | -5.56M | -5.68M |
| EPS Basic | -113.31 | -190.06 | -190.46 | -171.59 | -90.37 |
| Normalized Basic EPS | -6.15 | -54.12 | -51.51 | -54.60 | -54.60 |
| EPS Diluted | -113.31 | -190.06 | -190.46 | -171.59 | -90.37 |
| Normalized Diluted EPS | -6.15 | -54.12 | -51.51 | -54.60 | -54.60 |
| Average Basic Shares Outstanding | 1.45M | 926.50K | 394.50K | 331.40K | 331.40K |
| Average Diluted Shares Outstanding | 1.46M | 938.30K | 725.90K | 662.80K | 651.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |